Edition:
United States

Savara Inc (SVRA.OQ)

SVRA.OQ on NASDAQ Stock Exchange Global Select Market

11.34USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$11.34
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
54,039
52-wk High
$17.11
52-wk Low
$4.63

Chart for

About

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of... (more)

Overall

Beta: -0.19
Market Cap(Mil.): $345.88
Shares Outstanding(Mil.): 30.50
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 192.73 16.31
EPS (TTM): -- -- --
ROI: -- -0.67 35.74
ROE: -- -3.38 17.71

BRIEF-Savara Announces IND Approval For Expansion Of Molgradex Phase 3 Study Into U.S.

* SAVARA ANNOUNCES IND APPROVAL FOR EXPANSION OF MOLGRADEX PHASE 3 STUDY INTO U.S.

Feb 12 2018

BRIEF-Savara ‍Received $5 Mln Award For Development Of Aerovanc​

* SAVARA INC - ‍RECEIVED $5 MILLION AWARD FROM CYSTIC FIBROSIS FOUNDATION THERAPEUTICS FOR DEVELOPMENT OF AEROVANC​ Source text for Eikon: Further company coverage:

Nov 29 2017

BRIEF-Savara posts Q3 loss per share $0.28

* Savara reports third quarter 2017 financial results and provides business update

Nov 08 2017

BRIEF-SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

* SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Oct 25 2017

BRIEF-Savara announces proposed public offering of common stock

* Savara announces proposed public offering of common stock Source text for Eikon: Further company coverage:

Oct 24 2017

BRIEF-Savara expands molgradex development to include treatment of nontuberculous mycobacterial (NTM) lung infection

* Savara announces expansion of molgradex development to include treatment of nontuberculous mycobacterial (NTM) lung infection

Oct 24 2017

BRIEF-Savara reports completion of enrollment

* Savara reports completion of enrollment in phase 2 clinical trial of aironite for the treatment of hfpef

Oct 18 2017

BRIEF-Savara announces start of pivotal Phase III AVAIL study of AeroVanc

* Savara announces start of pivotal Phase III AVAIL study of AeroVanc Source text for Eikon: Further company coverage:

Sep 26 2017

BRIEF-Savara says entered into settlement agreement related to Serendex's acquisition

* Savara-On sept. 1, co, Serenova a/s entered into settlement agreement with respect to claim made by co related to Savara's acquisition of Serendex

Sep 07 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $35.74 --
Johnson & Johnson (JNJ.N) $129.91 --
Roche Holding Ltd. (ROG.S) CHF221.30 -2.00
Roche Holding Ltd. (RO.S) CHF224.80 -1.60
Sanofi SA (SASY.PA) €64.65 -0.24
GlaxoSmithKline plc (GSK.L) 1,295.20 -7.80

Earnings vs. Estimates